Evidence map›Paper›PMID 10926586›Full record

ArticleBMJ (Clinical research ed.)2000

Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies.

R Peto, S Darby, H Deo, P Silcocks, E Whitley, R Doll

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 414 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
414citing papers in PubMed, 12 pooled it
26.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02681848 unknown statusnot on this mapstarted 2006, after this paper: background citation

What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?

TypeobservationalSponsorUniversity of BristolRan2006 to 2019Enrolled180,000ConditionsSmoking Cessation, Cardiovascular Disease, Respiratory Disease, Myocardial InfarctionArmsVarenicline, Nicotine replacement therapy
NCT03654105 phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation

Multifactorial Intervention of Primary Prevention in High Risk Subjects: a Randomized Trial

TypeinterventionalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2019 to 2026Enrolled2,000ConditionsInflammation, Smoking Cessation, Diet Modification, Physical ActivityArmsCytisine, Acetylsalicylic acid, Diet Modification and Physical Activity Increase, early lung cancer detection, spirometry with CO test
3 · Its place in the literature

Who cites it

414 citing papers in PubMed, 12 syntheses or guidelines pooled it, 1,403 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Pooled it
  5. The Shared Genetic Architectures Between Lung Cancer and Multiple Polygenic Phenotypes in Genome-Wide Association Studies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018
    Guideline
  9. Pooled it
  10. Pooled it
  11. System change interventions for smoking cessation.The Cochrane database of systematic reviews · 2017
    Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.Cancer prevention research (Philadelphia, Pa.) · 2016
    Trial
  16. Relapse-Prevention Booklets as an Adjunct to a Tobacco Quitline: A Randomized Controlled Effectiveness Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016
    Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

354 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

R PetoClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Radcliffe Infirmary, Oxford OX2 6HE.
S Darby
H Deo
P Silcocks
E Whitley
R Doll

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVE AND

designTo relate UK national trends since 1950 in smoking, in smoking cessation, and in lung cancer to the contrasting results from two large case-control studies centred around 1950 and 1990.

settingUnited Kingdom.

participantsHospital patients under 75 years of age with and without lung cancer in 1950 and 1990, plus, in 1990, a matched sample of the local population: 1465 case-control pairs in the 1950 study, and 982 cases plus 3185 controls in the 1990 study.

main outcome measuresSmoking prevalence and lung cancer.

resultsFor men in early middle age in the United Kingdom the prevalence of smoking halved between 1950 and 1990 but the death rate from lung cancer at ages 35-54 fell even more rapidly, indicating some reduction in the risk among continuing smokers. In contrast, women and older men who were still current smokers in 1990 were more likely than those in 1950 to have been persistent cigarette smokers throughout adult life and so had higher lung cancer rates than current smokers in 1950. The cumulative risk of death from lung cancer by age 75 (in the absence of other causes of death) rose from 6% at 1950 rates to 16% at 1990 rates in male cigarette smokers, and from 1% to 10% in female cigarette smokers. Among both men and women in 1990, however, the former smokers had only a fraction of the lung cancer rate of continuing smokers, and this fraction fell steeply with time since stopping. By 1990 cessation had almost halved the number of lung cancers that would have been expected if the former smokers had continued. For men who stopped at ages 60, 50, 40, and 30 the cumulative risks of lung cancer by age 75 were 10%, 6%, 3%, and 2%.

conclusionsPeople who stop smoking, even well into middle age, avoid most of their subsequent risk of lung cancer, and stopping before middle age avoids more than 90% of the risk attributable to tobacco. Mortality in the near future and throughout the first half of the 21st century could be substantially reduced by current smokers giving up the habit. In contrast, the extent to which young people henceforth become persistent smokers will affect mortality rates chiefly in the middle or second half of the 21st century.

Indexed as

AdultAgedAge DistributionCase-Control StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedPrevalenceRisk FactorsSex DistributionSmokingSmoking CessationUnited Kingdom

Identifiers

PMID10926586
PMCPMC27446
OpenAlexW2077030176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.